FrankG.BasileMD

Oncology • Boston, MA

Hematologic Oncology

Executive Director-Clinical Development at Schrodinger

Join to view full profile

Dr. Basile is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Basile's full profile

Already have an account?

Office
22 Boston Wharf Rd
Boston, MA 02210

Summary

Dr. Frank Basile is an oncologist in Boston, MA. He received his medical degree from Rutgers New Jersey Medical School and has been in practice 21 years. He specializes in hematologic oncology and is experienced in lung cancer, multiple myeloma, oncology, lymphoproliferative disorder, and ovarian cancer. He has more than 10 publications and over 100 citings.

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Boston University Medical CenterResidency, Internal Medicine, 1998 - 2001
Tufts Medical CenterResidency, Pathology-Anatomic and Clinical, 1996 - 1998
Rutgers New Jersey Medical SchoolClass of 1996

Certifications & Licensure

MA State Medical License 2000 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection Start of enrollment: 2006 Jun 01
Completed
Phase 3
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
The Young Women's Breast Cancer Study Start of enrollment: 2006 Nov 01
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

6 citations
Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
Btissam Chami, Makoto Okuda, Morvarid Moayeri, France Pirenne, Yoko Hidaka
Transfusion. 2022-11-01
4 citations
Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants
Bin Fan, David Dai, Marvin Cohen, Huansheng Xu, Feng Yin
Clinical Pharmacology in Drug Development. 2021-01-01
43 citations
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Irene M. Ghobrial, Chia Jen Liu, Oksana Zavidij, Abdel Kareem Azab, Rachid Baz
American Journal of Hematology. 2019-11-01

Abstracts/Posters

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Frank Basile, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Frank G. Basile, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member